Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

The Lancet

Volumn 388, Issue 10057, 2016, Pages 2239-2253

  Viney, Nicholas J ^a   van Capelleveen, Julian C ^c,d   Geary, Richard S ^a   Xia, Shuting ^a   Tami, Joseph A ^a   Yu, Rosie Z ^a   Marcovina, Santica M ^b   Hughes, Steven G ^a   Graham, Mark J ^a   Crooke, Rosanne M ^a   Crooke, Stanley T ^a   Witztum, Joseph L ^e   Stroes, Erik S ^c   Tsimikas, Sotirios ^a,e  

^a ISIS PHARMACEUTICALS   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d CENTRAL LABORATORY   (Netherlands)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN A; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IONIS APO(A) RX; IONIS APO(A)L RX; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE A2; PHOSPHOLIPID; PLACEBO; PLASMINOGEN; SODIUM CHLORIDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTISENSE THERAPY; ARTICLE; BLEEDING; CANADA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DENMARK; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIRST IN HUMAN STUDY; FLU LIKE SYNDROME; GERMANY; HEART INFARCTION; HUMAN; INJECTION SITE REACTION; KIDNEY FUNCTION; LIPOPROTEIN BLOOD LEVEL; LIVER CELL; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NETHERLANDS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRESYNCOPE; PRIORITY JOURNAL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; GENETICS; RISK FACTOR; TREATMENT OUTCOME;

APOLIPOPROTEINS A; APOPROTEIN(A); CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; OLIGONUCLEOTIDES, ANTISENSE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84994607113     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31009-1     Document Type: Article

References (39)

1. 1 Willer, CJ, Schmidt, EM, Sengupta, S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet 45 (2013), 1274–1283.
2. 2 Clarke, R, Peden, JF, Hopewell, JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 361 (2009), 2518–2528.
3. 3 Kamstrup, PR, Tybjaerg-Hansen, A, Steffensen, R, Nordestgaard, BG, Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301 (2009), 2331–2339.
4. 4 Luke, MM, Kane, JP, Liu, DM, et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol 27 (2007), 2030–2036.
5. 5 Deloukas, P, Kanoni, S, Willenborg, C, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 45 (2013), 25–33.
6. 6 Cohen, JC, Boerwinkle, E, Mosley, TH Jr., Hobbs, HH, Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354 (2006), 1264–1272.
7. 7 Cannon, CP, Blazing, MA, Giugliano, RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
8. 8 Thanassoulis, G, Lipoprotein(a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis. J Lipid Res 57 (2016), 917–924.
9. 9 Kronenberg, F, Utermann, G, Lipoprotein(a): resurrected by genetics. J Int Med 273 (2013), 6–30.
10. 10 Capoulade, R, Chan, KL, Yeang, C, et al. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol 66 (2015), 1236–1246.
11. 11 Tsimikas, S, Duff, GW, Berger, PB, et al. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). J Am Coll Cardiol 63 (2014), 1724–1734.
12. 12 Tsimikas, S, Willeit, P, Willeit, J, et al. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol 60 (2012), 2218–2229.
13. 13 Byun, YS, Lee, JH, Arsenault, BJ, et al. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol 65 (2015), 1286–1295.
14. 14 Scipione, CA, Sayegh, SE, Romagnuolo, R, et al. Mechanistic insights into lipoprotein(a)-induced interleukin-8 expression: a role for oxidized phospholipid modification of apolipoprotein(a). J Lipid Res 56 (2015), 2273–2285.
15. 15 Yeang, C, Hung, M-Y, Byun, Y-S, et al. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B-100 and lipoprotein(a). J Clin Lipidol 10 (2016), 594–603.
16. 16 Albers, JJ, Slee, A, O'Brien, KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol 62 (2013), 1575–1579.
17. 17 Nestel, PJ, Barnes, EH, Tonkin, AM, et al. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. Arterioscler Thromb Vasc Biol 33 (2013), 2902–2908.
18. 18 Khera, AV, Everett, BM, Caulfield, MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation 129 (2014), 635–642.
19. 19 Guyton, JR, Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol 18 (2007), 415–420.
20. 20 Santos, RD, Raal, FJ, Catapano, AL, Witztum, JL, Steinhagen-Thiessen, E, Tsimikas, S, Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol 35 (2015), 689–699.
21. 21 Raal, FJ, Honarpour, N, Blom, DJ, et al., for the TESLA investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 385 (2015), 341–350.
22. 22 Tsimikas, S, Viney, NJ, Hughes, SG, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 386 (2015), 1472–1483.
23. 23 Prakash, TP, Graham, MJ, Yu, J, et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res 42 (2014), 8796–8807.
24. 24 Yeang, C, Witztum, JL, Tsimikas, S, ‘LDL-C’ = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. Curr Opin Lipidol 26 (2015), 169–178.
25. 25 Timmerman, I, Daniel, AE, Kroon, J, van Buul, JD, Leukocytes crossing the endothelium: a matter of communication. Int Rev Cell Mol Biol 322 (2016), 281–329.
26. 26 Marcovina, SM, Albers, JJ, Scanu, AM, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 46 (2000), 1956–1967.
27. 27 Seman, LJ, Breckenridge, WC, Isolation and partial characterization of apolipoprotein (a) from human lipoprotein (a). Biochem Cell Biol 64 (1986), 999–1009.
28. 28 Merki, E, Graham, M, Taleb, A, et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J Am Coll Cardiol 57 (2011), 1611–1621.
29. 29 Jenner, JL, Seman, LJ, Millar, JS, et al. The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings. Metabolism 54 (2005), 361–369.
30. 30 Kesaniemi, YA, Witztum, JL, Steinbrecher, UP, Receptor-mediated catabolism of low density lipoprotein in man. Quantitation using glucosylated low density lipoprotein. J Clin Invest 71 (1983), 950–959.
31. 31 Romagnuolo, R, Scipione, CA, Boffa, MB, Marcovina, SM, Seidah, NG, Koschinsky, ML, Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem 290 (2015), 11649–11662.
32. 32 Libby, P, Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 32 (2012), 2045–2051.
33. 33 Wiesner, P, Tafelmeier, M, Chittka, D, et al. MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma. J Lipid Res 54 (2013), 1877–1883.
34. 34 Kadl, A, Sharma, PR, Chen, W, et al. Oxidized phospholipid-induced inflammation is mediated by Toll-like receptor 2. Free Radic Biol Med 51 (2011), 1903–1909.
35. 35 Willeit, P, Kiechl, S, Kronenberg, F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol 64 (2014), 851–860.
36. 36 Kamstrup, PR, Tybjaerg-Hansen, A, Nordestgaard, BG, Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol 61 (2013), 1146–1156.
37. 37 Leebmann, J, Roeseler, E, Julius, U, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: Prospective observational multicenter study. Circulation 128 (2013), 2567–2576.
38. 38 Jaeger, BR, Richter, Y, Nagel, D, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 6 (2009), 229–239.
39. 39 Arai, K, Orsoni, A, Mallat, Z, et al. Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. J Lipid Res 53 (2012), 1670–1678.